<DOC>
	<DOCNO>NCT00714649</DOCNO>
	<brief_summary>Primary diagnose HNSCC carcinoma patient eligible curative surgery propose addition 2 3 neoadjuvant cetuximab infusion . The main objective reduce minimal delay time elapse last infusion surgery . Iterative biomarkers take 6 time point permit investigate expression gen profile protein mutation .</brief_summary>
	<brief_title>Neoadjuvant Cetuximab HNSCC Combined With Curative Surgery</brief_title>
	<detailed_description>This Phase I/II trial neoadjuvant cetuximab monotherapy preoperative treatment patient operable HNSCC . It monocenter study ( St-Luc university Hospital , Universit√© catholique de Louvain , Brussels ) . This part trial determine safe minimum delay neoadjuvant cetuximab infusion surgery . The aim investigate cetuximab give 24 hour surgery safe . Patients receive cetuximab load dose 400 mg/m2 first administration follow 250 mg/m2/week second third administration , applicable . The delay last administration cetuximab surgery progressively reduce ( Figure 1 ) . Five level pre-defined final administration 3 preoperative dos cetuximab 24-hour delay last dose cetuximab surgery . Level I : 10-12 day delay second cetuximab infusion surgery ( total 2 dos pre-op ) Level II : 6-8 day delay second cetuximab infusion surgery ( total 2 dos pre-op ) Level III : 3-4 day delay second cetuximab infusion surgery ( total 2 dos pre-op ) Level IV : 3-4 day delay third cetuximab infusion surgery ( total 3 dos pre-op ) Level V : 24-hour delay third cetuximab dose surgery ( total 3 dos pre-op ) The cohort size 3 patient per level , extend 6 patient one `` limiting toxicity '' observe . Decision rule classic 3+3 phase 1design ( Figure 2 ) . `` Limiting toxicity '' define ( ) life-threatening ( grade 4 ) surgical complication ( ii ) unexpected surgical grade 3 toxicity . Unexpected toxicity determine safety committee careful review patient file . The safety committee consist surgical team UCL Saint-Luc , one external surgeon , one representative Merck study coordinator . Patients treat level V evaluate like patient phase II part .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>More 18 year Histologically proven squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx patient select primary surgical treatment No distant metastases No active second malignancy last 5 year No prior concurrent evidence uncontrolled severe pathology preclude administration surgery life expectancy 3 month Not pregnant nursing ; fertile patient male female , must use effective contraception Signed informed consent Performance Status ECOG 01 Nasopharynx cancer Past current malignancy HNSCC performance Status ECOG 2 Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol Use investigationals agent within 4 week prior ti entry Previous exposure EGFR target therapy Known grade hypersensitivity cetuximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Head Neck Squamous Cell Carcinoma treat surgery</keyword>
	<keyword>and/or radiotherapy</keyword>
</DOC>